Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...
Daly provided Q2 guidance: "MACOM expects revenue in fiscal Q2 ending April 3, 2026, to be in the range of $281 million to $289 million. Adjusted gross margin is expected to be in the range of 57% to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results